May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting

May direct-acting antiviral regimens for chronic hepatitis C virus infections have... Drugs Ther Perspect (2017) 33:442–447 DOI 10.1007/s40267-017-0422-x ORIGINAL RESEARCH ARTICLE May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting 1 1 1 1 • • • Davide Simeone Anna Maria Spera G. Tosone R. Orlando Published online: 6 July 2017 Springer International Publishing AG 2017 Abstract mood (18.5%), hypochondria (18.5%), initial, middle and Background Until 2011, the standard-of-care therapy for delayed insomnia (14.8% for each type), fear (14.8%), chronic hepatitis C virus (HCV) infections relied on modification of the intellectual sphere (14.8%), and irri- pegylated interferon, whose psychiatric adverse drug tability (14.8%); no suicide attempt or depersonalization/ reactions are well known to treating physicians. From de-realization disorder were reported. No patients with- 2014, direct-acting antivirals (DAAs) with fewer adverse drew from therapy due to psychiatric adverse drug drug reactions and not contraindicated in patients affected reactions. by psychiatric disorders have been used. The aim of the Conclusions This pilot study seems to indicate that the present study is to assess the development of psychiatric occurrence of the psychiatric effects seems to be more effects related to DAA regimens based on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting

Loading next page...
 
/lp/springer_journal/may-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-virus-I6n04bW6Jg
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-017-0422-x
Publisher site
See Article on Publisher Site

Abstract

Drugs Ther Perspect (2017) 33:442–447 DOI 10.1007/s40267-017-0422-x ORIGINAL RESEARCH ARTICLE May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting 1 1 1 1 • • • Davide Simeone Anna Maria Spera G. Tosone R. Orlando Published online: 6 July 2017 Springer International Publishing AG 2017 Abstract mood (18.5%), hypochondria (18.5%), initial, middle and Background Until 2011, the standard-of-care therapy for delayed insomnia (14.8% for each type), fear (14.8%), chronic hepatitis C virus (HCV) infections relied on modification of the intellectual sphere (14.8%), and irri- pegylated interferon, whose psychiatric adverse drug tability (14.8%); no suicide attempt or depersonalization/ reactions are well known to treating physicians. From de-realization disorder were reported. No patients with- 2014, direct-acting antivirals (DAAs) with fewer adverse drew from therapy due to psychiatric adverse drug drug reactions and not contraindicated in patients affected reactions. by psychiatric disorders have been used. The aim of the Conclusions This pilot study seems to indicate that the present study is to assess the development of psychiatric occurrence of the psychiatric effects seems to be more effects related to DAA regimens based on

Journal

Drugs & Therapy PerspectivesSpringer Journals

Published: Jul 6, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off